209 related articles for article (PubMed ID: 36353623)
1. Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer.
Pan Y; Lu L; Liu H; Chen D; Han N; Yao R; Wang X; Gao X; Yu J; Chen L; Zhou F; Hao G; Lu Y; Li M; He G; Kang F; Li Z; Tang Y; Zhang J; Wei L; Nie Y
Front Immunol; 2022; 13():1003859. PubMed ID: 36353623
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer.
Li LL; Yu AY; Zhu M; Ma LY; Cao MH; Liu WL; Qin XB; Gao C; Han ZX; Wang HM
Arch Virol; 2024 May; 169(5):114. PubMed ID: 38700535
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of Epstein-Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy.
Kim EJ; Chae H; Park YS; Ryu MH; Kim HD; Shin J; Park YS; Moon MS; Kang YK
Gastric Cancer; 2024 Jan; 27(1):146-154. PubMed ID: 38006567
[TBL] [Abstract][Full Text] [Related]
4. Collision of Epstein-Barr virus-positive and -negative gastric cancer, diagnosed by molecular analysis: a case report.
Miyabe K; Saito M; Koyama K; Umakoshi M; Ito Y; Yoshida M; Kudo-Asabe Y; Saito K; Nanjo H; Maeda D; Matsusaka K; Goto A; Kono K
BMC Gastroenterol; 2021 Mar; 21(1):97. PubMed ID: 33653296
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494
[TBL] [Abstract][Full Text] [Related]
6. PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review.
Liao CX; Deng CS; Liang X; Yang JC; Chen ZZ; Lin XY; Lin CF; Chen S; Wu SS
Front Immunol; 2023; 14():1239168. PubMed ID: 37753076
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy.
Pereira MA; Batista DAM; Ramos MFKP; Cardili L; Ribeiro RRE; Dias AR; Zilberstein B; Ribeiro U; Cecconello I; Alves VAF; Mello ES
J Surg Res; 2021 May; 261():130-138. PubMed ID: 33429221
[TBL] [Abstract][Full Text] [Related]
8. The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer.
Wei XL; Liu QW; Liu FR; Yuan SS; Li XF; Li JN; Yang AL; Ling YH
Oncoimmunology; 2021; 10(1):1938381. PubMed ID: 34235004
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.
Sundar R; Qamra A; Tan ALK; Zhang S; Ng CCY; Teh BT; Lee J; Kim KM; Tan P
Gastric Cancer; 2018 Nov; 21(6):1064-1070. PubMed ID: 29915957
[TBL] [Abstract][Full Text] [Related]
10. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.
Sasaki S; Nishikawa J; Sakai K; Iizasa H; Yoshiyama H; Yanagihara M; Shuto T; Shimokuri K; Kanda T; Suehiro Y; Yamasaki T; Sakaida I
Gastric Cancer; 2019 May; 22(3):486-496. PubMed ID: 30264329
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Perspectives of STING and PD-L1 Expression and Correlation with the Prognosis of Epstein-Barr Virus-Associated Gastric Cancers.
Sun Q; Fu Y; Chen X; Li L; Wu H; Liu Y; Xu H; Zhou G; Fan X; Xia H
Gut Liver; 2022 Nov; 16(6):875-891. PubMed ID: 35611665
[TBL] [Abstract][Full Text] [Related]
12. Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma.
Masetti M; Lindinger M; Lorenzen S
Oncol Res Treat; 2022; 45(6):375-379. PubMed ID: 35220300
[TBL] [Abstract][Full Text] [Related]
13. Immune Landscape of Epstein-Barr Virus-Associated Gastric Cancer: Analysis From a Western Academic Institution.
Yee EJ; Gilbert D; Kaplan J; van Dyk L; Kim SS; Berg L; Clambey E; Wani S; McCarter MD; Stewart CL
J Surg Res; 2024 Apr; 296():742-750. PubMed ID: 38368775
[TBL] [Abstract][Full Text] [Related]
14. Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma.
Dong M; Wang HY; Zhao XX; Chen JN; Zhang YW; Huang Y; Xue L; Li HG; Du H; Wu XY; Shao CK
Hum Pathol; 2016 Jul; 53():25-34. PubMed ID: 26980034
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
[TBL] [Abstract][Full Text] [Related]
16. Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104/cadonilimab (PD-1/CTLA-4 bispecific): A case report.
Peng J; Zhu Q; Peng Z; Chen Z; Liu Y; Liu B
Front Immunol; 2022; 13():1049518. PubMed ID: 36569905
[TBL] [Abstract][Full Text] [Related]
17. Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1
Saito R; Abe H; Kunita A; Yamashita H; Seto Y; Fukayama M
Mod Pathol; 2017 Mar; 30(3):427-439. PubMed ID: 27934877
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
19. Complete response of a patient with advanced gastric cancer, showing Epstein-Barr virus infection, to preoperative chemotherapy with S-1 and cisplatin.
Seya T; Tanaka N; Yokoi K; Ishikawa N; Horiba K; Kanazawa Y; Yamada T; Koizumi M; Shinji S; Okazaki H; Ohaki Y; Ishiwata T; Naito Z; Tajiri T
Int J Clin Oncol; 2007 Dec; 12(6):472-7. PubMed ID: 18071868
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.
Yoon CJ; Chang MS; Kim DH; Kim W; Koo BK; Yun SC; Kim SH; Kim YS; Woo JH
Gastric Cancer; 2020 Sep; 23(5):780-795. PubMed ID: 32206940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
